Related Experiment Video
Updated: Mar 25, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster
Y Yan1, E A Hanse2,3, K Stedman2,4
1Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Abstract:
PHLPP2, a member of the PH-domain leucine-rich repeat protein phosphatase (PHLPP) family, which targets oncogenic kinases, has been actively investigated as a tumor suppressor in solid tumors. Little is known, however, regarding its regulation in hematological malignancies. We observed that PHLPP2 protein expression, but not its mRNA, was suppressed in late differentiation stage acute myeloid leukemia (AML) subtypes. MicroRNAs (miR or miRNAs) from the miR-17-92 cluster, oncomir-1, were shown to inhibit PHLPP2 expression and these miRNAs were highly expressed in AML cells that lacked PHLPP2 protein. Studies showed that miR-17-92 cluster regulation was, surprisingly, independent of transcription factors c-MYC and E2F in these cells; instead all-trans-retinoic acid (ATRA), a drug used for terminally differentiating AML subtypes, markedly suppressed miR-17-92 expression and increased PHLPP2 protein levels and phosphatase activity. Finally, we demonstrate that the effect of ATRA on miR-17-92 expression is mediated through its target, transcription factor C/EBPβ, which interacts with the intronic promoter of the miR-17-92 gene to inhibit transactivation of the cluster. These studies reveal a novel mechanism for upregulation of the phosphatase activity of PHLPP2 through C/EBPβ-mediated repression of the miR-17-92 cluster in terminally differentiating myeloid cells.
Insights
PHLPP2 protein is suppressed in acute myeloid leukemia (AML) by miR-17-92. All-trans-retinoic acid (ATRA) upregulates PHLPP2 by inhibiting miR-17-92 via C/EBPβ, revealing a novel therapeutic mechanism.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- PHLPP2, a tumor suppressor in solid tumors, has poorly understood regulation in hematological malignancies.
- PHLPP2 protein, but not mRNA, is suppressed in late-stage acute myeloid leukemia (AML).
Purpose of the Study:
- Investigate PHLPP2 regulation in AML.
- Identify mechanisms controlling PHLPP2 expression and activity in myeloid differentiation.
Main Methods:
- Analysis of PHLPP2 protein and mRNA expression in AML subtypes.
- Investigated the role of miR-17-92 cluster in PHLPP2 regulation.
- Assessed the effect of all-trans-retinoic acid (ATRA) on miR-17-92 and PHLPP2.
- Determined the role of transcription factor C/EBPβ in mediating ATRA's effect.
Main Results:
- miR-17-92 cluster directly inhibits PHLPP2 protein expression.
- High miR-17-92 expression correlates with low PHLPP2 protein in AML cells.
- ATRA suppresses miR-17-92, increasing PHLPP2 protein and activity.
- C/EBPβ mediates ATRA's repression of the miR-17-92 gene promoter.
Conclusions:
- A novel mechanism for PHLPP2 upregulation involves C/EBPβ-mediated repression of the miR-17-92 cluster.
- This pathway is crucial in terminally differentiating myeloid cells, offering therapeutic potential for AML.
Related Concept Videos
Abnormal Proliferation
Master Transcription Regulators
Cell Specific Gene Expression
Negative Regulator Molecules
Transcription Factors
Forced Transdifferentiation
Artificial...

